Sapropterin Dihydrochloride (Kuvan) vs Sepiapterin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Phenylketonuria

Shared mechanism: Phenylalanine hydroxylase (PAH) · full Phenylketonuria pipeline

Sapropterin Dihydrochloride (Kuvan)

Marketed by BioMarin Pharmaceutical

Approved in Phenylketonuriasmall molecule
Reliable signal

NCT00104247 · Phase 3 · completed

The trial randomized 89 participants to double-blind sapropterin or placebo, with 41 and 46 participants included in the primary analysis. Its primary endpoint, change in blood phenylalanine—a disease-defining physiological measure for phenylketonuria—was significantly better with sapropterin than placebo (p<0.001), supporting strong evidence from this study.

Reported efficacy

Change in Blood Phenylalanine Levels From Baseline to Week 6.: Change in Blood Phenylalanine Levels From Baseline to Week 6. (baseline to week 6): Sapropterin Dihydrochloride — Baseline Blood Phe Level: 843 micromole per liter (Standard Deviation 300); Week 6 Blood Phe Level: 607 micromole per liter (Standard Deviation 377); Mean Change in Blood Phe from Baseline to Week 6: -239 micromole per liter (Standard Deviation 38) | Placebo — Baseline Blood Phe Level: 888 micromole per liter (Standard Deviation 323); Week 6 Blood Phe Level: 891 micromole per liter (Standard Deviation 348); Mean Change in Blood Phe from Baseline to Week 6: 6 micromole per liter (Standard Deviation 36) (met)

Result source: NCT00104247

Sepiapterin

Marketed by PTC Therapeutics

Approved in Phenylketonuriasmall molecule
Reliable signal

NCT05099640 · Phase 3 · completed

Following an open-label run-in phase that identified patients who responded to sepiapterin, those responders were randomized in a double-blind, placebo-controlled comparison of 110 patients. The primary endpoint, blood phenylalanine level, fell by 63% with sepiapterin versus essentially no change with placebo, a highly statistically significant difference (p<0.0001).

Next expected readout: February 2031 · NCT06302348 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Phenylketonuria

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Sepiapterin: registry results are on file for Phenylketonuria, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Sapropterin Dihydrochloride (Kuvan)
Change in Blood Phenylalanine Levels From Baseline to Week 6. (baseline to week 6): Sapropterin Dihydrochloride — Baseline Blood Phe Level: 843 micromole per liter (Standard Deviation 300); Week 6 Blood Phe Level: 607 micromole per liter (Standard Deviation 377); Mean Change in Blood Phe from Baseline to Week 6: -239 micromole per liter (Standard Deviation 38) | Placebo — Baseline Blood Phe Level: 888 micromole per liter (Standard Deviation 323); Week 6 Blood Phe Level: 891 micromole per liter (Standard Deviation 348); Mean Change in Blood Phe from Baseline to Week 6: 6 micromole per liter (Standard Deviation 36) NCT00104247 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Phenylalanine supplement tolerated at week 10: sapropterin 20.9 (SD 15.4) vs placebo 2.9 (SD 4.0) mg/kg/day; mean difference 17.7 (SE 4.5) mg/kg/day, P<.001 (n=33 and 12) (Trefz et al., J Pediatr 2009). NCT00272792 · Phase 3 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Sapropterin Dihydrochloride (Kuvan)'s landscape · Sepiapterin's landscape